SynAct Pharma Logo

SynAct Pharma

SYNACT | ST

Overview

Corporate Details

ISIN(s):
SE0008241491 (+1 more)
LEI:
549300RRYIEFEQ72N546
Country:
Sweden
Address:
Scheelevägen 2, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SynAct Pharma is a clinical-stage biotechnology company focused on developing innovative medicines for inflammatory diseases. The company's core strategy centers on resolution therapy, an approach that aims to resolve, rather than inhibit, inflammatory processes by restoring the body's natural immune balance. Its lead candidate, resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development pipeline targets a wide spectrum of acute and chronic inflammatory conditions, such as rheumatoid arthritis, with the goal of reducing disease progression and offering a better-tolerated treatment alternative to establish a new standard of care.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for SynAct Pharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 07:30
Interim Report
Swedish 6.6 MB
2025-08-20 07:30
Interim Report
English 6.6 MB
2025-08-15 08:55
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter en andra konvertering av teckningsoptioner
Swedish 62.1 KB
2025-08-15 08:55
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after second conversion of warrants
English 61.3 KB
2025-08-05 11:34
Major Shareholding Notification
Swedish 10.6 KB
2025-07-31 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 59.6 KB
2025-07-31 18:00
Share Issue/Capital Change
Change in number of shares and votes in SynAct Pharma AB
English 59.3 KB
2025-07-15 22:13
Share Issue/Capital Change
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
English 61.8 KB
2025-07-15 22:13
Share Issue/Capital Change
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Swedish 62.8 KB
2025-07-15 21:00
Share Issue/Capital Change
SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Swedish 62.2 KB
2025-07-15 21:00
Share Issue/Capital Change
SynAct to receive SEK 17.7 million after conversion of warrants
English 61.3 KB
2025-07-11 13:28
Major Shareholding Notification
Swedish 10.6 KB
2025-06-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Förändring av antalet aktier och röster i SynAct Pharma AB
Swedish 59.0 KB
2025-06-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in SynAct Pharma AB
English 59.2 KB
2025-06-13 10:18
Major Shareholding Notification
Swedish 10.6 KB

Automate Your Workflow. Get a real-time feed of all SynAct Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SynAct Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-30 Anders Kronborg Other Buy 28,902 250,002.30 SEK
2024-06-01 Björn Westberg Other Other 516,205 N/A
2024-04-30 Jeppe Øvlesen Other Other 58,139 499,995.40 SEK
2024-04-30 Anders Kronborg Other Other 34,883 299,993.80 SEK
2024-03-21 Jeppe Øvlesen Other Other 245,870 1,696,503.00 SEK
2023-11-09 Thomas Jonassen Other Other 3,531,644 22,072,775.00 SEK
2023-11-09 Thomas Jonass Other Other 2,161,225 13,507,656.25 SEK
2023-01-16 Jeppe Øvlesen Other Other 1,161,777 72,727,240.20 SEK
2023-01-16 James Knight Other Other 77,452 4,848,495.20 SEK
2023-01-16 Thomas Boesen Other Other 32,917 2,060,604.20 SEK

Peer Companies

Company Country Ticker View
United States of America N/A
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
Saniona Logo
Biopharma developing medicines for epilepsy and neurological disorders using ion channel research.
Denmark SANION
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
Scandion Oncology A/S Logo
A liquidated biotech that developed oral drugs to overcome cancer treatment resistance.
Denmark SCOL
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Sensorion Logo
Clinical-stage biotech developing novel therapies for hearing loss, vertigo, and tinnitus.
France ALSEN
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS